Both prescription and over-the-counter (OTC) drugs must be manufactured in accordance with standards established by the Food and Drug Administration (FDA). The agency inspects manufacturing facilities before a drug application can be approved. Any manufacturing deficiencies found would need to be corrected before approval.
Current Good Manufacturing Practices (cGMPs) refers to the regulations enforced by the FDA.
Adherence to the cGMP regulations assures the identity, strength, quality, and purity of drug products by requiring that manufacturers of medications adequately control manufacturing operations. This includes establishing strong quality management systems, obtaining appropriate quality raw materials, establishing robust operating procedures, detecting and investigating product quality deviations, and maintaining reliable testing laboratories. This formal system of controls at a pharmaceutical company, if adequately put into practice, helps to prevent instances of contamination, mix-ups, deviations, failures, and errors. This assures that drug products meet their quality standards.
The cGMP requirements were established to be flexible in order to allow each manufacturer to decide individually how to best implement the necessary controls by using scientifically sound design, processing methods, and testing procedures. The flexibility in these regulations allows companies to use modern technologies and innovative approaches to achieve higher quality through continual improvement.
- Use of RFID in serialized unique packaging numbering to authenticate and check for recall/expiry status.
- Use of X-ray and metal detection systems to detect glass, stone, bone, rubber and other contaminants
- Use of checkweighers and sorters
- Use of baggers capable of handling, opening and sealing bags manufactured from specialist sterile films and papers.
- Use of quality control labeling systems
It is important to note that cGMPs are minimum requirements. Many pharmaceutical manufacturers are already implementing comprehensive, modern quality systems and risk management approaches that exceed these minimum standards. This is important because a consumer cannot detect through smell, touch, or sight if a drug product is safe or if it will work.
All reports in Manufacturing, Packaging & Detailing
|
Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
5/15/2012 | published by: GBI Research
... research, “Orphan Disease Therapeutics in Genetic Disorders to 2018 - Emerging Agents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity”, which provides insights into the global orphan diseases in genetic disorders therapeutics ...
|
more...
|
$3,500.00
|
|
Outsourcing in Drug Discovery: The Contract Research Organization (CRO) Market, 5th Edition
5/11/2012 | published by: Kalorama Information
... target protein or nucleic acid in a way that is useful for treatment of disease. The process by which molecules are identified for their therapeutic value involves synthesis and analysis of many derivatives of the ...
|
more...
|
$3,995.00
|
|
Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules
4/30/2012 | published by: GBI Research
... latest research “Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential despite Moderate Scope of Current Late Stage Molecules”, which provides insights into the Oncology orphan disease therapeutics ...
|
more...
|
$3,500.00
|
|
Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion
4/30/2012 | published by: GBI Research
... Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion”, which provides insights into the cytotoxic therapies market until 2017 for eight oncology indications. The ...
|
more...
|
$3,500.00
|
|
Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation
4/30/2012 | published by: GBI Research
... “Orphan Disease Therapeutics Market to 2018 - Improved Understanding of Rare Diseases' Heterogeneity and Novel New Clinical Trial Designs to Foster Innovation”, which provides insights into the orphan disease therapeutics market until 2018. The report ...
|
more...
|
$3,500.00
|
|
Contract Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs
4/20/2012 | published by: GBI Research
... Manufacturing Organizations to 2018 - Cost Advantages and Improving Quality Standards Build Confidence and Encourage Foreign Investment in Asian CMOs”, which provides key data, information and analysis of the Contract Manufacturing Organization (CMO) industry. The ...
|
more...
|
$3,500.00
|
|
Biological Product (except Diagnostic) Manufacturing Industry in the U.S. and its International Trade [2012 Q2 Release]
4/16/2012 | published by: Supplier Relations US, LLC
... upstream and downstream industries, and trade data. This 2012 report's 168 pages and over 150 charts and tables cover the domestic market, global market and overseas growth opportunities. Find the latest data on shipments, inventory, ...
|
more...
|
$599.00
|
|
Pharmaceutical Preparation Manufacturing Industry in the U.S. and its International Trade [2012 Q2 Release]
4/16/2012 | published by: Supplier Relations US, LLC
... downstream industries, and trade data. This 2012 report's 173 pages and over 150 charts and tables cover the domestic market, global market and overseas growth opportunities. Find the latest data on shipments, inventory, international trade, ...
|
more...
|
$799.00
|
|
Anti-Infective Pharmaceuticals Market in India 2012
4/6/2012 | published by: Netscribes (India) Pvt. Ltd.
... It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the patient population, increasing number of vaccine approvals, increase in health insurances and introduction of newer ...
|
more...
|
$795.00
|
|
Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment
4/2/2012 | published by: GBI Research
... its latest research “Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington’s Disease Segment”, which provides insights into the CNS orphan ...
|
more...
|
$3,500.00
|
|
India Pharmaceutical Industry Research and Forecast to 2016
4/1/2012 | published by: AM Mindpower Solutions
... analyses major bio-pharmaceutical market segments, top therapeutic categories and traditional medicine market (herbal drugs, ayurvedic and homeopathy). Report also include SWOT analysis, major driving forces, industry growth barriers, Opportunities, Regulatory structure, Macro economy factors and ...
|
more...
|
$850.00
|
|
Canada Pharmaceutical Industry
4/1/2012 | published by: Aruvian's R'search
... and Spain and has shown a steady growth trend. The Canadian pharmaceutical industry is gradually becoming more favorable towards generic drugs rather than branded drugs. Pfizer is Canada's leading pharmaceutical company and generic manufacturer Apotex ...
|
more...
|
$325.00
|
|
Herpes Market to 2018 - Genericization Compels Competitors Seeking Differentiation to Adopt Novel Drug Delivery Technologies
4/1/2012 | published by: GBI Research
... Technologies finds that the global herpes market is an attractive one, and is expected to witness growth during the forecast period and to provide good opportunities for investors. The expected high growth is attributed to ...
|
more...
|
$3,500.00
|
|
Generic And Innovative Drugs Market In Central Europe 2012
4/1/2012 | published by: PMR Ltd.
... 2012-2014 details the current market structures, policies and procedures for reimbursement in Poland, Romania, Slovakia, the Czech Republic, Hungary and Bulgaria. This timely report features complete information on new legislative developments occurring in each country ...
|
more...
|
$3,500.00
|
|
Tensions Rising between Branded Drugmakers and Health Plans
3/31/2012 | published by: GlobalData
... Large pharmaceutical companies are in the midst of a wave of patent expirations that is threatening their profitability. As drugmakers face numerous impending patent expirations, they are exploring new options to squeeze revenue out of ...
|
more...
|
$500.00
|
|
Anti-Diabetic Pharmaceuticals Market in India 2012
3/30/2012 | published by: Netscribes (India) Pvt. Ltd.
... a huge demand for anti-diabetic drugs. It is a highly fragmented market with a large number of foreign and domestic players. The huge increase in the number of diabetes cases, introduction of newer and better ...
|
more...
|
$795.00
|
|
Global Pharmaceuticals & Medicine Manufacturing
3/27/2012 | published by: IBISWorld
... be segmented between prescription-based (or ethical) products and over-the-counter medications. The products are predominantly distributed via wholesalers and are then sold via pharmacies or distributed in hospitals. This report covers the scope, size, disposition and ...
|
more...
|
$935.00
|
|
Pharma Leader Series: Top 50 Generic Drug Manufacturers 2012-2022
3/26/2012 | published by: Visiongain
... 2012 to 2022. See how companies worldwide are performing and where they are heading. There, you find analytical profiles for leading producers - activities, outlooks and prospects: Teva Pharmaceutical Industries Sandoz Mylan Actavis Hospira Watson ...
|
more...
|
$2,642.00
|
|
Neurometabolic Disorders Market to 2017 - Novel Therapies for Rare Diseases such as Gaucher’s and Niemann-Pick Poised to Supersede Existing Therapies
3/23/2012 | published by: GBI Research
... Novel Therapies for Rare Diseases such as Gaucher’s and Niemann-Pick Poised to Supersede Existing Therapies” which provides insights into global neurometabolic disorders market and market forecast until 2017. Report is built using data and information ...
|
more...
|
$3,500.00
|
|
Brand Name Pharmaceutical Manufacturing in the US - Industry Market Research Report
3/21/2012 | published by: IBISWorld
... biosimilar drugs will be an important area of growth for the industry, though a major increase in taxes and discounts to fill the Medicare coverage gap will likely hamper revenue growth. Brand-name pharmaceutical and medicine ...
|
more...
|
$910.00
|
|
Peru Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
... which reflect multinationals’concern over inadequate patent protection and market access barriers that include the requirement thatimport quality is now assessed on an ad hoc, country-by-country basis. Headline Expenditure Projections .. Pharmaceuticals: PEN3.35bn (US$1.22bn) in 2011 ...
|
more...
|
$1,175.00
|
|
Switzerland Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
... a result of the increased prevalence of chronic disease with age, thereforeconsuming a disproportionately large share of healthcare services. Such robust demand for services overthe coming years means the government will need to adapt strategies ...
|
more...
|
$1,175.00
|
|
Bangladesh Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
... epidemiological changes will continue to stimulate demand forpharmaceutical treatments and medical devices, risks will remain elevated, partly on account of theunsettled political situation. Multinational companies will continue to suffer due to the country’s patentfreeregime, even ...
|
more...
|
$530.00
|
|
Canada Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
... maintain it is highly unlikely the Canadian governmentwill introduce punitive price controls like those witnessed across Europe. Instead, the country’shealthcare market will continue to place downward pressures on pharmaceutical prices as policiesmandating generic substitution compress ...
|
more...
|
$1,175.00
|
|
Kuwait Pharmaceuticals and Healthcare Report Q2 2012
3/20/2012 | published by: Business Monitor International
... increasingly challenging operating environment across the GulfCooperation Council (GCC) as a whole. We still expect Kuwait’s pharmaceutical market to growsteadily, driven by epidemiological and demographic changes, as well as healthcare system reform, butthe distributors of ...
|
more...
|
$1,175.00
|


